Aire Advisors LLC Sells 2,739 Shares of Johnson & Johnson (NYSE:JNJ)

Aire Advisors LLC decreased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 21.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,112 shares of the company's stock after selling 2,739 shares during the period. Aire Advisors LLC's holdings in Johnson & Johnson were worth $1,677,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of JNJ. WealthTrak Capital Management LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at about $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth about $29,000. Conquis Financial LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth about $33,000. Bernard Wealth Management Corp. acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth about $36,000. Finally, Runnymede Capital Advisors Inc. acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth about $38,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock traded up $3.54 on Tuesday, hitting $167.90. 9,277,637 shares of the company traded hands, compared to its average volume of 8,146,116. The firm's 50-day simple moving average is $154.29 and its 200 day simple moving average is $155.12. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The company has a market cap of $403.99 billion, a P/E ratio of 17.96, a P/E/G ratio of 2.08 and a beta of 0.41. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The firm's quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm earned $2.82 EPS. Analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.10%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Royal Bank Of Canada increased their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research report on Thursday, July 17th. Finally, Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Eleven research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus target price of $172.87.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.